Onyx Pharmaceuticals Stock Rating Reaffirmed by Deutsche Bank (ONXX)
The analysts wrote, “Guidelines updated on Friday add Kyprolis in combo with Revlimid & Dex as an option for patients who are transplant candidates with a category 2A classification (low-evidence but uniform NCCN consensus). It has been included as an ‘other regimen.’ We are not sure what differences there are in other vs. preferred for ease of reimbursement, but we think that inclusion as other is definitely a positive first step.”
ONXX has been the subject of a number of other recent research reports. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Onyx Pharmaceuticals in a research note to investors on Monday. They now have a $96.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Onyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Friday. They now have a $88.00 price target on the stock.
Sixteen investment analysts have rated the stock with a buy rating, two have assigned an overweight rating, and four have given a hold rating to the company’s stock. Onyx Pharmaceuticals presently has an average rating of “buy” and a consensus target price of $100.88.
Onyx Pharmaceuticals traded up 2.55% on Monday, hitting $87.83. Onyx Pharmaceuticals has a 52-week low of $36.53 and a 52-week high of $93.18. The stock’s 50-day moving average is currently $76.80. The company’s market cap is $6.324 billion.
Onyx Pharmaceuticals last released its earnings data on Thursday, February 21st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.40. The company had revenue of $127.90 million for the quarter, compared to the consensus estimate of $113.17 million. During the same quarter last year, the company posted $1.50 earnings per share. Onyx Pharmaceuticals’s revenue was down 46.0% compared to the same quarter last year. On average, analysts predict that Onyx Pharmaceuticals will post $-2.41 earnings per share for the current fiscal year.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.